Multidisciplinary therapy managements in endometrial and renal cancer patients treated with pembrolizumab and lenvatinib: a virtuous circle between oncologists and organ specialists

A strong rationale supports the combination of an immunocheckpoint inhibitor (ICI) and an antiangiogenic agent in different tumor types such as endometrial cancer (EC) and renal cell carcinoma (RCC). Accordingly, the combination of pembrolizumab plus lenvatinib demonstrated the efficacy in pretreated advanced EC and metastatic RCC, and to optimize drugs administration a more in-depth knowledge of adverse events management for the combination is needed. We analyzed the most common toxicities for appropriate and proactive management to maximize the efficacy of the tyrosine kinase inhibitor (TKI)-ICI combination and a summary of the most relevant recommendations on the management of organ specific disorders was produced. A multidisciplinary approach is suggested, involving collaboration between oncologists and organ specialists to promptly prevent/address possible toxicities associated with the treatment.